Patients
ONCOLOGY, METASTASIS
Enrollment occurred between 11/1999 and 10/2002. We characterized the subset of survivors as a separate group for descriptive analysis. One patient survived for a period of 16.97 years after enrollment and died a year before the 20-year follow-up; the participant was included in the group of survivors for the descriptive analysis. Age, ECOG status, and estrogen/progesterone receptor (ER/PR) status were similarly balanced between groups. Patient characteristics are summarized in Patient characteristics at baseline.Abbreviations: ECOG: Eastern Cooperative Oncology Group; UOQ: upper outer quadrant; NOS: not otherwise specified; UIQ: upper inner quadrant; LOQ: lower outer quadrant; CMF: cytoxan + methotrexate + 5-fluoracil; AC: adriamycin + cytoxan; SERM: selective estrogen receptor modulator.Most participants had visceral metastasis on enrollment (